Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Lymphoid Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01460134
What this trial is testing

CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Who this might be right for
CD27 Expressing B-cell Malignancies for Example Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+7 more
Celldex Therapeutics 90
Testing effectiveness (Phase 2)UnknownNCT00002532
What this trial is testing

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Who this might be right for
Leukemia
Hannover Medical School
Early research (Phase 1)Study completedNCT01523977
What this trial is testing

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Who this might be right for
Acute Lymphoblastic Leukemia
Dana-Farber Cancer Institute 22
Early research (Phase 1)Study completedNCT00002912
What this trial is testing

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

Who this might be right for
Leukemia
National Cancer Institute (NCI) 3
Testing effectiveness (Phase 2)Study completedNCT01462253
What this trial is testing

Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults

Who this might be right for
Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 35
Testing effectiveness (Phase 2)Looking for participantsNCT04047641
What this trial is testing

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaBlasts 20 Percent or More of Bone Marrow Nucleated CellsHigh Risk Myelodysplastic Syndrome+5 more
M.D. Anderson Cancer Center 80
Early research (Phase 1)Study completedNCT00012207
What this trial is testing

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Fred Hutchinson Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT00448357
What this trial is testing

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 54
Early research (Phase 1)Study completedNCT03236857
What this trial is testing

The Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Who this might be right for
MalignanciesAcute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)+2 more
AbbVie 143
Testing effectiveness (Phase 2)Study completedNCT01369849
What this trial is testing

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)UnknownNCT05576532
What this trial is testing

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

Who this might be right for
T-lymphoblastic LymphomaRelapsed DiseaseRefractory Lymphoma+3 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 30
Early research (Phase 1)Study completedNCT04139434
What this trial is testing

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Who this might be right for
AML/MDSCMMLRelapse+3 more
Newave Pharmaceutical Inc 32
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Testing effectiveness (Phase 2)Ended earlyNCT01383447
What this trial is testing

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Who this might be right for
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Ended earlyNCT00112723
What this trial is testing

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+25 more
National Cancer Institute (NCI) 46
Large-scale testing (Phase 3)Study completedNCT02393859
What this trial is testing

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Leukemia, Acute Lymphoblastic
Amgen 111
Testing effectiveness (Phase 2)Active Not RecruitingNCT03277729
What this trial is testing

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+20 more
Fred Hutchinson Cancer Center 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT01589302
What this trial is testing

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Who this might be right for
Prolymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory/Relapsed Chronic Lymphocytic Leukemia
Kami Maddocks, MD 154
Large-scale testing (Phase 3)Looking for participantsNCT06943872
What this trial is testing

Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines 630
Testing effectiveness (Phase 2)Looking for participantsNCT06644183
What this trial is testing

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
LeukemiaRelapsed LeukemiaChronic Lymphocytic Leukemia+2 more
Jennifer R. Brown, MD, PhD 64
Next Page